Preferred embodiments of the present invention are related to a novel therapeutic drug combination for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to a therapeutic combination comprising a Rho-kinase inhibitor, such as fasudil, and an endothelin receptor antagonist such as bosentan.